<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35390090</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases.</ArticleTitle><Pagination><StartPage>e0266529</StartPage><MedlinePgn>e0266529</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0266529</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0266529</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The occurrence of autoimmune diseases (AIDs) in amyotrophic lateral sclerosis (ALS) patients is widely reported, but little is known about the associated clinical phenotype. This study aims to evaluate the clinical features and prognosis of ALS patients with AID.</AbstractText><AbstractText Label="METHODS">This retrospective study was based on the ALS Registry dataset of Peking Union Medical College Hospital from 2013 to 2020. Clinical features and inflammatory biomarkers at registration were compared between ALS patients with coexisting AIDs and those without (controls). The medical records of immunotherapy were also collected. The Kaplan-Meier method and Cox proportional hazard model were used to study the survival of ALS patients.</AbstractText><AbstractText Label="RESULTS">There are 26 (1.6%) ALS patients with AIDs in our database. The ALS patients with AIDs had older ages at onset and poorer respiratory function than controls (p&lt;0.05). After propensity score matching by sex, onset age, and disease duration, the difference in respiratory function remained significant between groups. We found no differences in overall survival between ALS patients with and without AIDs before and after matching (p = 0.836; p = 0.395). Older age at onset, rapid disease progression, and lower erythrocyte sedimentation rate (ESR) were associated with shorter survival (p&lt;0.05). Among ALS patients with AIDs, 8 (30.8%) had a history of immunotherapy and showed slightly prolonged survival compared with those without immunotherapy, but the results did not reach statistical significance (p = 0.355).</AbstractText><AbstractText Label="CONCLUSIONS">Patients with coexisting ALS and AIDs had older onset age and poorer respiratory function but similar overall survival than those with pure ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jin-Yue</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiao-Han</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Dong-Chao</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xun-Zhe</ForeName><Initials>XZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ming-Sheng</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Li-Ying</ForeName><Initials>LY</Initials><Identifier Source="ORCID">0000-0002-5369-1541</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="Y">Acquired Immunodeficiency Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35390090</ArticleId><ArticleId IdType="pmc">PMC8989203</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0266529</ArticleId><ArticleId IdType="pii">PONE-D-21-30948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. J Neurol Neurosurg Psychiatry 2017; 88:540&#x2013;549. 10.1136/jnnp-2016-315018</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis[J]. Neurotherapeutics 2015; 12:364&#x2013;75. 10.1007/s13311-014-0329-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis[J]. Curr Opin Neurol 2018; 31:635&#x2013;639. 10.1097/WCO.0000000000000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Trageser KJ, Smith C, Herman FJ, Ono K, Pasinetti GM. Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia[J]. Front Neurosci 2019; 13:1298. 10.3389/fnins.2019.01298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01298</ArticleId><ArticleId IdType="pmc">PMC6914852</ArticleId><ArticleId IdType="pubmed">31920478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia[J]. J Clin Invest 2017; 127:3250&#x2013;3258. 10.1172/JCI90607</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munter J, Shafarevich I, Liundup A, Pavlov D, Wolters EC, Gorlova A, et al.. Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice[J]. CNS Neurosci Ther 2020; 26:504&#x2013;517. 10.1111/cns.13280</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13280</ArticleId><ArticleId IdType="pmc">PMC7163689</ArticleId><ArticleId IdType="pubmed">31867846</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis[J]. J Neurol Sci 1993; 118:169&#x2013;74. doi: 10.1016/0022-510x(93)90106-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(93)90106-9</ArticleId><ArticleId IdType="pubmed">8229065</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective[J]. Int Immunol 2015; 27:117&#x2013;29. 10.1093/intimm/dxu099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu099</ArticleId><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Forns X, Bosch X, Graus F, Navarro M, Font J. Amyotrophic lateral sclerosis in a patient with systemic lupus erythematosus[J]. Lupus 1993; 2:133&#x2013;4. 10.1177/096120339300200212</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339300200212</ArticleId><ArticleId IdType="pubmed">8330035</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado ME, Williams RC Jr., Adair JC, Hart BL, Gregg L, Sibbitt WL Jr. Neuropsychiatric systemic lupus erythematosus presenting as amyotrophic lateral sclerosis[J]. J Rheumatol 2002; 29:633&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11908583</ArticleId></ArticleIdList></Reference><Reference><Citation>Schady W, Metcalfe RA, Holt PJ. Rheumatoid arthritis and motor neurone disease&#x2014;an association?[J]. Br J Rheumatol 1989; 28:70&#x2013;3. 10.1093/rheumatology/28.1.70</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/28.1.70</ArticleId><ArticleId IdType="pubmed">2917234</ArticleId></ArticleIdList></Reference><Reference><Citation>Padovan M, Caniatti LM, Trotta F, Govoni M. Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature[J]. Rheumatol Int 2011; 31:715&#x2013;9. 10.1007/s00296-010-1760-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1760-3</ArticleId><ArticleId IdType="pubmed">21258799</ArticleId></ArticleIdList></Reference><Reference><Citation>Loustau V, Foltz V, Poulain C, Rozenberg S, Bruneteau G. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFalpha blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFalpha blockers?[J]. Joint Bone Spine 2009; 76:213&#x2013;4. 10.1016/j.jbspin.2008.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2008.07.004</ArticleId><ArticleId IdType="pubmed">18955008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrabet H, Borhani-Haghighi A, Koseoglu E, Mutlu M, Baydemir R, Nafissi S, et al.. Association of amyotrophic lateral sclerosis and Behcet&#x2019;s disease: is there a relationship? A multi-national case series[J]. Clin Rheumatol 2012; 31:733&#x2013;8. 10.1007/s10067-011-1923-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-011-1923-y</ArticleId><ArticleId IdType="pubmed">22234492</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Ouchi H, Shimbo J, Sato A, Yamazaki M, Hashidate H, et al.. Coexistence of amyotrophic lateral sclerosis with neuro-Behcet&#x2019;s disease presenting as a longitudinally extensive spinal cord lesion: clinicopathologic features of an autopsied patient[J]. Neuropathology 2014; 34:185&#x2013;9. 10.1111/neup.12074</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12074</ArticleId><ArticleId IdType="pubmed">24118427</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemadifar M, Abtahi SH, Akbari M, Maghzi AH. Multiple sclerosis and amyotrophic lateral sclerosis: is there a link?[J]. Mult Scler 2012; 18:902&#x2013;4. 10.1177/1352458511427719</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511427719</ArticleId><ArticleId IdType="pubmed">22146612</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study[J]. Neurology 2013; 81:1222&#x2013;5. 10.1212/WNL.0b013e3182a6cc13</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Longinetti E, Larsson H, Andersson J, Pawitan Y, Piehl F, et al.. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study[J]. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22:211&#x2013;219. 10.1080/21678421.2020.1861022</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1861022</ArticleId><ArticleId IdType="pubmed">33331190</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW, et al.. Prior medical conditions and the risk of amyotrophic lateral sclerosis[J]. J Neurol 2014; 261:1949&#x2013;56. 10.1007/s00415-014-7445-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7445-1</ArticleId><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, Guo X, Huang R, Cao B, et al.. The predictors of survival in Chinese amyotrophic lateral sclerosis patients[J]. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16:237&#x2013;44. 10.3109/21678421.2014.993650</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.993650</ArticleId><ArticleId IdType="pubmed">25581512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al.. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis[J]. Neurology 2015; 84:2247&#x2013;57. 10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang W, Li Y, Mo R, Wang J, Qiu L, Ou C, et al.. Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China[J]. Neurol Sci 2020; 41:1211&#x2013;1223. 10.1007/s10072-019-04146-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04146-1</ArticleId><ArticleId IdType="pubmed">31897952</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, et al.. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China[J]. BMC Gastroenterol 2010; 10:100. 10.1186/1471-230X-10-100</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-100</ArticleId><ArticleId IdType="pmc">PMC2944334</ArticleId><ArticleId IdType="pubmed">20815889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CF, See LC, Yu KH, Chou IJ, Tseng WY, Chang HC, et al.. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan[J]. Scand J Rheumatol 2011; 40:373&#x2013;8. 10.3109/03009742.2011.553736</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2011.553736</ArticleId><ArticleId IdType="pubmed">21388247</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al.. Epidemiology of primary Sjogren&#x2019;s syndrome: a systematic review and meta-analysis[J]. Ann Rheum Dis 2015; 74:1983&#x2013;9. 10.1136/annrheumdis-2014-205375</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205375</ArticleId><ArticleId IdType="pubmed">24938285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen HH, Weng MT, Tung CC, Wang YT, Chang YT, Chang CH, et al.. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study[J]. Intest Res 2019; 17:54&#x2013;62. 10.5217/ir.2018.00096</Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2018.00096</ArticleId><ArticleId IdType="pmc">PMC6361021</ArticleId><ArticleId IdType="pubmed">30449079</ArticleId></ArticleIdList></Reference><Reference><Citation>Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases[J]. World J Gastroenterol 2017; 23:6137&#x2013;6146. 10.3748/wjg.v23.i33.6137</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i33.6137</ArticleId><ArticleId IdType="pmc">PMC5597505</ArticleId><ArticleId IdType="pubmed">28970729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases[J]. J Autoimmun 2009; 33:197&#x2013;207. 10.1016/j.jaut.2009.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2009.09.008</ArticleId><ArticleId IdType="pmc">PMC2783422</ArticleId><ArticleId IdType="pubmed">19819109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease[J]. Nat Immunol 2018; 19:665&#x2013;673. 10.1038/s41590-018-0120-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0120-4</ArticleId><ArticleId IdType="pmc">PMC7882196</ArticleId><ArticleId IdType="pubmed">29925983</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies[J]. Lancet Neurol 2019; 18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjaeldgaard AL, Pilely K, Olsen KS, Pedersen SW, Lauritsen AO, Moller K, et al.. Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis[J]. Mol Immunol 2018; 102:14&#x2013;25. 10.1016/j.molimm.2018.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.06.007</ArticleId><ArticleId IdType="pubmed">29933890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemminki K, Li X, Sundquist J, Sundquist K. Familial risks for amyotrophic lateral sclerosis and autoimmune diseases[J]. Neurogenetics 2009; 10:111&#x2013;6. 10.1007/s10048-008-0164-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-008-0164-y</ArticleId><ArticleId IdType="pubmed">19089474</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CY, Yang TM, Ou RW, Wei QQ, Shang HF. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases[J]. BMC Med 2021; 19:27. 10.1186/s12916-021-01903-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01903-y</ArticleId><ArticleId IdType="pmc">PMC7863260</ArticleId><ArticleId IdType="pubmed">33541344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadoth A, Nefussy B, Bleiberg M, Klein T, Artman I, Drory VE. Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis[J]. JAMA Neurol 2015; 72:676&#x2013;81. 10.1001/jamaneurol.2015.48</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.48</ArticleId><ArticleId IdType="pubmed">25867286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialova L, Svarcova J, Bartos A, Ridzon P, Malbohan I, Keller O, et al.. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis[J]. Eur J Neurol 2010; 17:562&#x2013;6. 10.1111/j.1468-1331.2009.02853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02853.x</ArticleId><ArticleId IdType="pubmed">19968709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentes C, de Carvalho M, Valente I, Sales Luis ML, da Silva JP. Amyotrophic lateral sclerosis syndrome associated with connective tissue disease; improvement after immunosuppressive therapy. A long-term follow-up case[J]. Eur J Neurol 1999; 6:239&#x2013;40. 10.1111/j.1468-1331.1999.tb00019.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.1999.tb00019.x</ArticleId><ArticleId IdType="pubmed">10053238</ArticleId></ArticleIdList></Reference><Reference><Citation>Attout H, Rahmeh F, Ziegler F. [de Gorgerot-Sjogren syndrome simulating amyotrophic lateral sclerosis][J]. Rev Med Interne 2000; 21:708&#x2013;10. doi: 10.1016/s0248-8663(00)80030-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0248-8663(00)80030-2</ArticleId><ArticleId IdType="pubmed">10989500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases[J]. Autoimmun Rev 2003; 2:119&#x2013;25. doi: 10.1016/s1568-9972(03)00006-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1568-9972(03)00006-5</ArticleId><ArticleId IdType="pubmed">12848952</ArticleId></ArticleIdList></Reference><Reference><Citation>Watad A, Bragazzi NL, Adawi M, Amital H, Toubi E, Porat BS, et al.. Autoimmunity in the Elderly: Insights from Basic Science and Clinics&#x2014;A Mini-Review[J]. Gerontology 2017; 63:515&#x2013;523. 10.1159/000478012</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000478012</ArticleId><ArticleId IdType="pubmed">28768257</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosato E, Salsano F. Immunity, autoimmunity and autoimmune diseases in older people[J]. J Biol Regul Homeost Agents 2008; 22:217&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19036223</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M. Interleukin-6 and amyotrophic lateral sclerosis[J]. J Neurol Sci 2019; 398:50&#x2013;53. 10.1016/j.jns.2019.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al.. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis[J]. Acta Neurol Scand 2009; 119:383&#x2013;9. 10.1111/j.1600-0404.2008.01112.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2008.01112.x</ArticleId><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei QQ, Hou YB, Zhang LY, Ou RW, Cao B, Chen YP, et al.. Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis[J]. Neural Regen Res 2022; 17:875&#x2013;880. 10.4103/1673-5374.322476</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.322476</ArticleId><ArticleId IdType="pmc">PMC8530123</ArticleId><ArticleId IdType="pubmed">34472488</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration[J]. Curr Opin Neurol 2021; 34:765&#x2013;772. 10.1097/WCO.0000000000000983</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId><ArticleId IdType="pubmed">34402459</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis[J]. Brain 2020; 143:3526&#x2013;3539. 10.1093/brain/awaa309</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>